ValuEngine Lowers Nektar Therapeutics (NKTR) to Strong Sell
ValuEngine cut shares of Nektar Therapeutics (NASDAQ:NKTR) from a sell rating to a strong sell rating in a report released on Friday.
Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a hold rating and set a $54.00 target price on shares of Nektar Therapeutics in a report on Tuesday, July 31st. TheStreet upgraded Nektar Therapeutics from a d rating to a c rating in a report on Wednesday, August 8th. Mizuho reiterated a buy rating and set a $103.00 target price on shares of Nektar Therapeutics in a report on Thursday, August 9th. BidaskClub upgraded Nektar Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, August 14th. Finally, William Blair reiterated an outperform rating on shares of Nektar Therapeutics in a report on Thursday, August 9th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $85.78.
NKTR opened at $38.23 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.93 and a quick ratio of 13.80. Nektar Therapeutics has a 12 month low of $33.50 and a 12 month high of $111.36. The firm has a market capitalization of $6.62 billion, a P/E ratio of -69.51 and a beta of 2.91.
In other news, Director Jeffrey Robert Ajer sold 6,750 shares of the stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the transaction, the director now directly owns 15,750 shares in the company, valued at approximately $893,970. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Scott Greer sold 10,000 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the transaction, the director now owns 140,333 shares of the company’s stock, valued at $9,457,040.87. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,750 shares of company stock valued at $2,855,830. Corporate insiders own 4.31% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Macquarie Group Ltd. lifted its position in Nektar Therapeutics by 966.0% during the second quarter. Macquarie Group Ltd. now owns 165,000 shares of the biopharmaceutical company’s stock worth $8,057,000 after acquiring an additional 149,522 shares during the last quarter. World Asset Management Inc lifted its position in Nektar Therapeutics by 16.6% during the second quarter. World Asset Management Inc now owns 10,646 shares of the biopharmaceutical company’s stock worth $520,000 after acquiring an additional 1,513 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Nektar Therapeutics by 241.0% during the second quarter. Riverhead Capital Management LLC now owns 7,134 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 5,042 shares during the last quarter. Gateway Investment Advisers LLC acquired a new stake in Nektar Therapeutics during the second quarter worth approximately $342,000. Finally, LMR Partners LLP acquired a new stake in Nektar Therapeutics during the second quarter worth approximately $6,378,000. Institutional investors own 91.42% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Read More: Bond
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.